Right now, that's none other than Eli Lilly (NYSE: LLY). However, others are looking to challenge its dominance. Recent ...

Recursion Pharmaceuticals ( RXRX 1.39%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.

Novo Nordisk and Eli Lilly denied weight-loss drug partnership with Mangoceuticals on Thursday, hours after the telehealth ...

South Korean clinical-stage biotech ABL Bio has entered license, research and collaboration agreement with US pharma major Eli Lilly for the development of therapeutics by utilizing ABL Bio’s Grabody ...

After a rapid rise, Eli Lilly needs only an 11% gain to hit $1 trillion in market value. Revenue is expected to rise 26% next ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Shortly after crossing the FDA’s finish line, Ionis Pharmaceuticals’ RNA-targeted hereditary angioedema (HAE) treatment ...

Now, it’s worth noting Stock Advisor’s total average return is 1,062% — a market-crushing outperformance compared to 194 % ...

Ireland’s leprechaun economics phase, coined after the economy grew by 26 per cent in 2016, came on foot of the iPhone ...

Eli Lilly and Novo Nordisk’s competition in weight-loss drugs has affected thousands of jobs between Charlotte and Raleigh. Who is winning?